Workpackage 2  : Cell Production




• Develop market-ready allogeneic MSC production to make this technology widely available in the clinic and provide all the cells needed for the clinical trial.

• Optimize cell transport for better and longer viability over 48 hours.

• Improve and validate the cell expansion protocols to maximize the yield of cells and to reduce or remove xenogeneic components.

• Improve cryopreservation protocols so that cell loss becomes below 10% (by functional measurements).



UNAV, UVa, Univercell Biosolutions and Citopsin participate to this workpackage.